Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer

Molecular Therapy

Volumn 20, Issue 9, 2012, Pages 1821-1830

  Hemminki, Otto ^a   Diaconu, Iulia ^a   Cerullo, Vincenzo ^a   Pesonen, Saila K ^a   Kanerva, Anna ^a,b   Joensuu, Timo ^c   Kairemo, Kalevi ^c   Laasonen, Leena ^c   Partanen, Kaarina ^c   Kangasniemi, Lotta ^d   Lieber, Andre ^e   Pesonen, Sari ^a   Hemminki, Akseli ^a,c,d  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c International Comprehensive Cancer Center Docrates   (Finland)

^d Oncos Therapeutics Inc   (Finland)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; E1A PROTEIN; NEUTRALIZING ANTIBODY; ONCOLYTIC ADENOVIRUS; ONCOLYTIC ADENOVIRUS 3; ONCOLYTIC ADENOVIRUS 5; TELOMERASE REVERSE TRANSCRIPTASE; TEMOZOLOMIDE; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ANEMIA; ANIMAL TISSUE; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW DISEASE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPENIA; DIARRHEA; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; INJECTION SITE PAIN; LEUKOPENIA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; MOUSE; NAUSEA; NEUROBLASTOMA; NEUROLOGIC DISEASE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; RHABDOMYOSARCOMA; SARCOMA; SEROTYPE; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; THYROID CANCER; TOXICITY TESTING; VIRUS REPLICATION;

ADENOVIRIDAE; MUS;

EID: 84867037132     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.115     Document Type: Article

References (45)

1. Edukulla, R, Ramakrishna, E, Woller, N, Mundt, B, Knocke, S, Gürlevik, E et al. (2009). Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses. Cancer Res 69: 1448-1458.
2. Gürlevik, E, Woller, N, Strüver, N, Schache, P, Kloos, A, Manns, MP et al. (2010). Selectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity. Mol Ther 18: 1972-1982.
3. Bernt, KM, Ni, S, Tieu, AT and Lieber, A (2005). Assessment of a combined, adenovirus-mediated oncolytic and immunostimulatory tumor therapy. Cancer Res 65: 4343-4352. (Pubitemid 40775673)
4. Choi, KJ, Kim, JH, Lee, YS, Kim, J, Suh, BS, Kim, H et al. (2006). Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther 13: 1010-1020. (Pubitemid 43905854)
5. Hanahan, D and Weinberg, RA (2011). Hallmarks of cancer: the next generation. Cell 144: 646-674.
6. Mellman, I, Coukos, G and Dranoff, G (2011). Cancer immunotherapy comes of age. Nature 480: 480-489.
7. Kanerva, A and Hemminki, A (2004). Modifed adenoviruses for cancer gene therapy. Int J Cancer 110: 475-480. (Pubitemid 38658011)
8. Kanerva, A, Mikheeva, GV, Krasnykh, V, Coolidge, CJ, Lam, JT, Mahasreshti, PJ et al. (2002). Targeting adenovirus to the serotype 3 receptor increases gene transfer effciency to ovarian cancer cells. Clin Cancer Res 8: 275-280. (Pubitemid 34101488)
9. Kangasniemi, L, Kiviluoto, T, Kanerva, A, Raki, M, Ranki, T, Sarkioja, M et al. (2006). Infectivity-enhanced adenoviruses deliver effcacy in clinical samples and orthotopic models of disseminated gastric cancer. Clin Cancer Res 12: 3137-3144. (Pubitemid 43837362)
10. Tsuruta, Y, Pereboeva, L, Glasgow, JN, Rein, DT, Kawakami, Y, Alvarez, RD et al. (2007). A mosaic fber adenovirus serotype 5 vector containing reovirus sigma 1 and adenovirus serotype 3 knob fbers increases transduction in an ovarian cancer ex vivo system via a coxsackie and adenovirus receptor-independent pathway. Clin Cancer Res 13: 2777-2783. (Pubitemid 46788047)
11. Zheng, S, Ulasov, IV, Han, Y, Tyler, MA, Zhu, ZB and Lesniak, MS (2007). Fiber-knob modifcations enhance adenoviral tropism and gene transfer in malignant glioma. J Gene Med 9: 151-160. (Pubitemid 46523533)
12. Kanerva, A, Wang, M, Bauerschmitz, GJ, Lam, JT, Desmond, RA, Bhoola, SM et al. (2002). Gene transfer to ovarian cancer versus normal tissues with fber-modifed adenoviruses. Mol Ther 5: 695-704. (Pubitemid 34619062)
13. Hemminki, A, Wang, M, Desmond, RA, Strong, TV, Alvarez, RD and Curiel, DT (2002). Serum and ascites neutralizing antibodies in ovarian cancer patients treated with intraperitoneal adenoviral gene therapy. Hum Gene Ther 13: 1505-1514.
14. Hemminki, O, Bauerschmitz, G, Hemmi, S, Lavilla-Alonso, S, Diaconu, I, Guse, K et al. (2011). Oncolytic adenovirus based on serotype 3. Cancer Gene Ther 18: 288-296.
15. Wang, H, Li, ZY, Liu, Y, Persson, J, Beyer, I, Möller, T et al. (2011). Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med 17: 96-104.
16. Wang, H, Li, Z, Yumul, R, Lara, S, Hemminki, A, Fender, P et al. (2011). Multimerization of adenovirus serotype 3 fber knob domains is required for effcient binding of virus to desmoglein 2 and subsequent opening of epithelial junctions. J Virol 85: 6390-6402.
17. Fender, P, Boussaid, A, Mezin, P and Chroboczek, J (2005). Synthesis, cellular localization, and quantifcation of penton-dodecahedron in serotype 3 adenovirus-infected cells. Virology 340: 167-173. (Pubitemid 41317491)
18. Trinh, HV, Lesage, G, Chennamparampil, V, Vollenweider, B, Burckhardt, CJ, Schauer, S et al. (2012). Avidity binding of human adenovirus serotypes 3 and 7 to the membrane cofactor CD46 triggers infection. J Virol 86: 1623-1637.
19. Kim, KH, Ryan, MJ, Estep, JE, Miniard, BM, Rudge, TL, Peggins, JO et al. (2011). A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profle of ad5/3-?24 in advance of a phase I clinical trial in ovarian cancer patients. Hum Gene Ther 22: 821-828.
20. Sarkioja, M, Kanerva, A, Salo, J, Kangasniemi, L, Eriksson, M, Raki, M et al. (2006). Noninvasive imaging for evaluation of the systemic delivery of capsid-modifed adenoviruses in an orthotopic model of advanced lung cancer. Cancer 107: 1578-1588. (Pubitemid 44546919)
21. Ranki, T, Särkioja, M, Hakkarainen, T, von Smitten, K, Kanerva, A and Hemminki, A (2007). Systemic effcacy of oncolytic adenoviruses in imagable orthotopic models of hormone refractory metastatic breast cancer. Int J Cancer 121: 165-174. (Pubitemid 46753865)
22. Brunetti-Pierri, N, Palmer, DJ, Beaudet, AL, Carey, KD, Finegold, M and Ng, P (2004). Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 15: 35-46. (Pubitemid 38147187)
23. Morral, N, O'Neal, WK, Rice, K, Leland, MM, Piedra, PA, Aguilar-Córdova, E et al. (2002). Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons. Hum Gene Ther 13: 143-154. (Pubitemid 34075178)
24. Cerullo, V, Seiler, M P, Mane, V, Brunetti-Pierri, N, Clarke, C, Bertin, TK et al. (2007). Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther 15: 378-385. (Pubitemid 46111889)
25. Pesonen, S, Diaconu, I, Cerullo, V, Escutenaire, S, Raki, M, Kangasniemi, L et al. (2012). Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer 130: 1937-1947.
26. Koski, A, Kangasniemi, L, Escutenaire, S, Pesonen, S, Cerullo, V, Diaconu, I et al. (2010). Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 18: 1874-1884.
27. Leen, AM, Sili, U, Vanin, EF, Jewell, AM, Xie, W, Vignali, D et al. (2004). Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specifc CD8+ T cells. Blood 104: 2432-2440. (Pubitemid 39331844)
28. Nokisalmi, P, Pesonen, S, Escutenaire, S, Särkioja, M, Raki, M, Cerullo, V et al. (2010). Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res 16: 3035-3043.
29. Kannanganat, S, Ibegbu, C, Chennareddi, L, Robinson, HL and Amara, RR (2007). Multiple-cytokine-producing antiviral CD4 T cells are functionally superior to single-cytokine-producing cells. J Virol 81: 8468-8476. (Pubitemid 47242819)
30. Badr, G, Bédard, N, Abdel-Hakeem, MS, Trautmann, L, Willems, B, Villeneuve, JP et al. (2008). Early interferon therapy for hepatitis C virus infection rescues polyfunctional, long-lived CD8+ memory T cells. J Virol 82: 10017-10031.
31. Carlisle, RC, Di, Y, Cerny, AM, Sonnen, AF, Sim, RB, Green, NK et al. (2009). Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood 113: 1909-1918.
32. Escutenaire, S, Cerullo, V, Diaconu, I, Ahtiainen, L, Hannuksela, P, Oksanen, M et al. (2011). In vivo and in vitro distribution of type 5 and fber-modifed oncolytic adenoviruses in human blood compartments. Ann Med 43: 151-163.
33. Cerullo, V, Pesonen, S, Diaconu, I, Escutenaire, S, Arstila, PT, Ugolini, M et al. (2010). Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 70: 4297-4309.
34. Kanerva, A. American Society of Gene and Cell Therapy. Philadelphia, 2012.
35. Chen, J, Zajac, AJ, McPherson, SA, Hsu, HC, Yang, P, Wu, Q et al. (2005). Primary adenovirus-specifc cytotoxic T lymphocyte response occurs after viral clearance and liver enzyme elevation. Gene Ther 12: 1079-1088. (Pubitemid 40946150)
36. Brahmer, JR, Drake, CG, Wollner, I, Powderly, JD, Picus, J, Sharfman, WH et al. (2010). Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28: 3167-3175.
37. Postow, M, Callahan, MK and Wolchok, JD (2011). Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy. Cancer J 17: 372-378.
38. Liikanen, I, Monsurrò, V, Ahtiainen, L, Raki, M, Hakkarainen, T, Diaconu, I et al. (2011). Induction of interferon pathways mediates in vivo resistance to oncolytic adenovirus. Mol Ther 19: 1858-1866.
39. Dhar, D, Spencer, JF, Toth, K and Wold, WS (2009). Effect of preexisting immunity on oncolytic adenovirus vector INGN 007 antitumor effcacy in immunocompetent and immunosuppressed Syrian hamsters. J Virol 83: 2130-2139.
40. Sirena, D, Ruzsics, Z, Schaffner, W, Greber, UF and Hemmi, S (2005). The nucleotide sequence and a frst generation gene transfer vector of species B human adenovirus serotype 3. Virology 343: 283-298. (Pubitemid 41598366)
41. Reid, TR, Freeman, S, Post, L, McCormick, F and Sze, DY (2005). Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther 12: 673-681. (Pubitemid 41045565)
42. Pesonen, S, Nokisalmi, P, Escutenaire, S, Särkioja, M, Raki, M, Cerullo, V et al. (2010). Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther 17: 892-904.
43. Cerullo, V, Diaconu, I, Kangasniemi, L, Rajecki, M, Escutenaire, S, Koski, A et al. (2011). Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther 19: 1737-1746.
44. Liikanen, IAL, Kangasniemi, L, Cerullo, V, Nokisalmi, P, Escutenaire, S, Diaconu, I et al. (2011) Treatment of cancer with oncolytic adenovirus combined with temozolomide, an autophagy inducer. Mol Ther.
45. Fleischli, C, Sirena, D, Lesage, G, Havenga, MJ, Cattaneo, R, Greber, UF et al. (2007). Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on the membrane cofactor protein CD46 receptor. J Gen Virol 88(Pt 11): 2925-2934. (Pubitemid 350131229)